Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 11, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Repurchased: 500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,311.00 pence per share; lowest price paid was 1,295.00 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,163,910,311 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 500,000 repurchased shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price range (1,295.00 to 1,311.00 pence).
- Confirm the updated total issued share capital following the cancellation of the repurchased shares.
- Review the impact of the 8.72% Treasury share holding on future earnings per share calculations.
- Note that this filing does not contain operational or financial performance data for the period.